🔎 Trials Near Me

Dachaigh › Leukemia myeloid geur › Arkansas

Sgrùdaidhean clionaigeach Leukemia myeloid geur ann an Arkansas

Tha 13 sgrùdaidhean airson Leukemia myeloid geur a’ lorg phàirtichean aig làraichean ann an Arkansas.

Bailtean ann an Arkansas

Teacsa sgrùdaidh oifigeil (Beurla)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mercy Hospital Fort Smith, Fort Smith
  • CARTI Cancer Center, Little Rock
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 40 gu 75 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • University of Arkansas for Medical Sciences, Little Rock
A’ fastadhÌre 2
Aoisean 18 gu 59 · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • University of Arkansas at Little Rock, Little Rock
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • University of Arkansas for Medical Sciences, Little Rock
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • University of Arkansas for Medical Sciences, Little Rock
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • University of Arkansas for Medical Sciences, Little Rock
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • University of Arkansas for Medical Sciences, Little Rock
A’ fastadhÌre 2
Aoisean 18 gu 59 · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Arkansas Children's Hospital, Little Rock
A’ fastadhÌre 3
6 Months – 21 Years · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT04293562

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

  • Arkansas Children's Hospital, Little Rock
A’ fastadhÌre 3
Aoisean 1 gu 25 · Gach gnè · Air ùrachadh 4 Sult 2026 · NCT07022678

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Arkansas Children's Hospital, Little Rock
A’ fastadhÌre 1/2
Suas gu aois 22 · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  • Arkansas Children's Hospital, Little Rock
A’ fastadhÌre 3
29 Days – 21 Years · Gach gnè · Air ùrachadh 24 Lùna 2026 · NCT05183035

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Arkansas Children's Hospital, Little Rock
A’ fastadhSgrùdadh amharc
Gach aois · Gach gnè · Air ùrachadh 6 Iuch 2026 · NCT01351545

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

  • Arkansas Children's Hospital, Little Rock
A’ fastadhÌre 1
Suas gu aois 21 · Gach gnè · Air ùrachadh 22 Gibl 2026 · NCT05101551

Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.